390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

• Thomas Davis,
• Jessica Price,
• Ammar Sukari,
• Roger Cohen,
• Przemyslaw Twardowski,
• Jessica Flechtner,
• Melissa Johnson,
• Maura Gillison,
• Rudy Lackner,
• Arthur DeCillis,
• Richard Hernandez,
• Kevin Mancini,
• Mara Shainheit

Affiliations

Thomas Davis

7Genocea Biosciences, Centreville, MD, USA

Jessica Price

GOSH

Ammar Sukari

Aff238 grid.254444.70000000114567807Karmanos Cancer Institute Detroit MI USA

Roger Cohen

Aff452 grid.25879.310000000419368972University of Pennsylvania Philadelphia PA USA

Przemyslaw Twardowski

Aff5 grid.410425.60000000404218357City of Hope Duarte CA USA

Jessica Flechtner

Aff1 grid.475330.60000000405579162Genocea Biosciences, Inc Cambridge MA USA

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Maura Gillison

2MD Anderson Cancer Center, Houston, TX, USA

Rudy Lackner

6University of Nebraska, Omaha, NE, USA

Arthur DeCillis

7Genocea Biosciences, Centreville, MD, USA

Richard Hernandez

7Genocea Biosciences, Centreville, MD, USA

Kevin Mancini

7Genocea Biosciences, Centreville, MD, USA

Mara Shainheit

7Genocea Biosciences, Centreville, MD, USA